Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Doug Cole
AddedFeb 13, 2024
UpdatedMay 31, 2026
Doug Cole

Doug Cole

Board Member, Ensemble Discovery

CrunchbaseThe Org

Doug Cole's Career

Ensemble Discovery
Ensemble Discovery

Cambridge, MA, US

Board Member· Board
Repertoire Immune Medicines
Repertoire Immune Medicines

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Doug Cole's Career

Ensemble Discovery
Ensemble Discovery
Series B$30M132002Cambridge, MA, US
Board Member· Board

Leadership at Ensemble Discovery

Robert NelsenRobert NelsenBoard Member
David LiuDavid LiuCo-Founder
Repertoire Immune Medicines
Repertoire Immune Medicines
Series B$257.3M1752015Cambridge, MA, US
Board Member· Board

Leadership at Repertoire Immune Medicines

Torben Straight NissenTorben Straight NissenCEO
Stephen BerensonStephen BerensonBoard Member
Ewen CameronEwen CameronFounder

Similar to Repertoire Immune Medicines

INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
InimmuneInimmuneMissoula, MT, USImmunotherapeuticsest. 2016InimmuneMissoula, MT, US · est. 2016

Inimmue: A cutting-edge biotech firm, pioneering next-gen immunotherapeutics.

Series A · $22.6M15
Immunitas TherapeuticsImmunitas TherapeuticsWaltham, MA, USCancer Therapeuticsest. 2019Immunitas TherapeuticsWaltham, MA, US · est. 2019

US-based Immunitas advances immuno-oncology therapeutics through an integrated genomics platform.

Series B · $97M33
Ernexa TherapeuticsErnexa TherapeuticsCambridge, MA, USCell Therapiesest. 1984Ernexa TherapeuticsCambridge, MA, US · est. 1984

Eterna Therapeutics: Pioneering cell engineering for cancer and immunologic disease treatment.

Public · $49.1M11

People Similar to Doug Cole

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailAdam KoppelAdam KoppelBoard Member · Solid BiosciencesAdrian GottschalkAdrian GottschalkBoard Member · Foghorn TherapeuticsJim MullenJim MullenBoard Member · Thermo Fisher thEdward FitzgeraldEdward FitzgeraldBoard Member · Fog PharmaceuticalsFred DotzlerFred DotzlerBoard Member · Bayhill TherapeuticsMike BonneyMike BonneyBoard Member · Alnylam Pharmaceuticals aln